ES2108679T3 - Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer. - Google Patents

Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.

Info

Publication number
ES2108679T3
ES2108679T3 ES88310540T ES88310540T ES2108679T3 ES 2108679 T3 ES2108679 T3 ES 2108679T3 ES 88310540 T ES88310540 T ES 88310540T ES 88310540 T ES88310540 T ES 88310540T ES 2108679 T3 ES2108679 T3 ES 2108679T3
Authority
ES
Spain
Prior art keywords
sample
oncoproteins
against cancer
pattern
therapies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310540T
Other languages
English (en)
Inventor
Henry Lee Niman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2108679T3 publication Critical patent/ES2108679T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN METODO DE DIAGNOSIS, POR EJEMPLO, PARA DETECTAR LA PRESENCIA O GRAVEDAD DEL CANCER, INCLUYE PONER EN CONTACTO UNA MUESTRA DEL CUERPO, POR EJEMPLO ORINA, CON DOS MOLECULAS RECEPTORAS DIFERENTES POR LO MENOS, PARA GENERAR UN PRIMER PATRON DE REACTIVIDAD. ESTE PATRON SE PUEDE GENERAR COMO MONOCLONAL QUE ENLAZA A POLIPEPTIDOS EN LA MUESTRA QUE SE CODIFICA POR ENCOGENES, Y LUEGO SE COMPARA CON UN SEGUNDO PATRON DE REACTIVIDAD GENERADO POR UNA MUESTRA BIOLOGICA CONOCIDA. ESTA MUESTRA CONOCIDA ES INDICATIVA DE LA EXPRESION ENCOGENE O SECUENCIAS RELACIONADAS CON ENCOGENES. TAMBIEN SE DESCRIBEN CONJUNTOS PARA DIAGNOSTICO QUE UTILIZAN ESTE METODO, DONDE LOS RESULTADOS SE PUEDEN INTERPRETAR MEDIANTE EXPLORADOR AUTOMATICO.
ES88310540T 1987-11-09 1988-11-09 Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer. Expired - Lifetime ES2108679T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11882387A 1987-11-09 1987-11-09

Publications (1)

Publication Number Publication Date
ES2108679T3 true ES2108679T3 (es) 1998-01-01

Family

ID=22380954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88310540T Expired - Lifetime ES2108679T3 (es) 1987-11-09 1988-11-09 Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.

Country Status (10)

Country Link
US (1) US20030215894A1 (es)
EP (1) EP0318179B1 (es)
JP (1) JPH03500928A (es)
AT (1) ATE157172T1 (es)
AU (2) AU2497388A (es)
CA (1) CA1339069C (es)
DE (1) DE3856004T2 (es)
ES (1) ES2108679T3 (es)
GR (1) GR3025378T3 (es)
WO (1) WO1989004489A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
JP2726264B2 (ja) * 1986-05-06 1998-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ‐ｍｙｃタンパク質のためのアッセイ及び抗体
EP0354808B1 (en) * 1988-08-12 1997-12-03 Ligand Pharmaceuticals Incorporated Polypeptide-induced monoclonal receptors to protein ligands
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US6489451B1 (en) 1997-04-10 2002-12-03 Hefei-Siu-Fung Ustc Pharmaceutical Co., Ltd. Antithrombosis enzyme from the snake venom of agkistrodon acutus
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US7794946B1 (en) * 1998-02-04 2010-09-14 Life Technologies Corporation Microarray and uses therefor
EP1057032B1 (en) * 1998-02-18 2003-04-23 Theryte Limited Treating cancer
WO2007084631A2 (en) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535058A (en) * 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0206065A3 (en) * 1985-06-27 1989-04-19 James R. Feramisco Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids

Also Published As

Publication number Publication date
DE3856004D1 (de) 1997-09-25
DE3856004T2 (de) 1997-12-18
JPH03500928A (ja) 1991-02-28
GR3025378T3 (en) 1998-02-27
AU2967792A (en) 1993-02-11
AU665591B2 (en) 1996-01-11
CA1339069C (en) 1997-07-29
ATE157172T1 (de) 1997-09-15
WO1989004489A1 (en) 1989-05-18
EP0318179A2 (en) 1989-05-31
US20030215894A1 (en) 2003-11-20
AU2497388A (en) 1989-05-11
EP0318179A3 (en) 1990-08-01
EP0318179B1 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
ES2108679T3 (es) Utilizacion de receptores monoclonales frente a oncoproteinas para vigilar terapias contra el cancer.
US3720760A (en) Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
Nydegger et al. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
ATE133453T1 (de) Verfahren zur bestimmung von glukose in vollblut sowie gefäss und fotometer zur durchführung dieses verfahrens
ES2036667T3 (es) Metodo de ensayo que utiliza particulas con un fluorescedor asociado.
SE7701901L (sv) Instrument for bestemmande av halten av emnesomsettningsprodukter i blod
NO904001L (no) Fremgangsmaate og apparat, for diagnostisk analyse.
DE3587724D1 (de) Antikörper verwendende diagnostische Methoden.
ES2086969T3 (es) Procedimiento y dispositivo para el analisis de glucosa en una matriz biologica.
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
ES2114860T3 (es) Medicion no invasiva de la glucosa en la sangre.
ES2155513T3 (es) Ensayo de escrutinio para la deteccion precoz de neoplasia colorrectal.
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
ZA895068B (en) Process and reagent for the determination of a specifically bindable substance
ES2068860T3 (es) Potenciacion de señal en un ensayo para una enzima.
ES8504218A1 (es) Sistema de diagnostico de parasitosis y alergias
RU2009509C1 (ru) Способ прогнозирования течения псориаза
JPS6423141A (en) Transparency measuring method
AU6817487A (en) Pregnancy test with epf
AU586235B2 (en) Assay for salicylate and apparatus for performing same
HU9602558D0 (en) Means for treating auto-immune diseases and method of treatment
CN209915953U (zh) 一种皮肤检测装置
JPS5327494A (en) Enzyme analysis and apparatus therefor
MX2021000215A (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
GB1413800A (en) Diagnosis of viral diseases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 318179

Country of ref document: ES